Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Status:
Recruiting
Trial end date:
2023-01-05
Target enrollment:
Participant gender:
Summary
This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma
(MM) patients that are refractory to lenalidomide-containing regimens with or without
steroids.